Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To test this, 60 patients from a large (n = 117), previously unreported, clinical trial of GH treatment were randomly assigned to begin conjugated estrogens at either 12 or 15 yr of age.

Why It Was Studied

Clinical trials of recombinant human GH therapy in Turner syndrome that began more than a decade ago show that GH accelerates the linear growth rate.

The age at which feminization is induced could be an important factor in determining the patient's ultimate growth response.

Who Took Part

The abstract describes 60 patients taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

What Was Measured

PubMed files the paper under topics including Aging, Body Height, Bone Development, Estrogen Replacement Therapy, Feminization, Growth Hormone and Turner Syndrome.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 60 patients.

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.